Inhibikase Therapeutics IKT
NASDAQ IKT
$1.63 -0.03 (-1.81%)
At close: Oct 22, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Interest Paid (2020 - 2022)

Updated

Analysis

Inhibikase Therapeutics (IKT) Interest Paid (2020 - 2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Paid (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 339.00 Mn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 1.07 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 1.25 Bn
10 Inhibikase Therapeutics 283.68 Mn -301.80 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 973.00
Dec 31, 2021 -18,460.00
Jun 30, 2021 7,811.00
Mar 31, 2021 11,797.00
Dec 31, 2020 1,729.00
Sep 30, 2020 1,388.00
Jun 30, 2020 1,360.00
Mar 31, 2020 1,772.00
API Access

Inhibikase Therapeutics Interest Paid API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-paid&ticker=IKT&period=max&api_key=YOUR_API_KEY